Priscilla Cascetta

Medical Oncologist, thoracic malignancies

[Marco Tagliamento @M_Tagliamento]

Great to be included in the 2025 @EORTC Mentoring and Career Development Program! The event got off to a great start with two days of in-person meeting that just concluded. Amazing initiative!

[Meyer May-Lucie @mayluciemeyer]

The answer to your question is Paris. #ELCC2025 @thelouisgros @PCascetta @JordiRemon @peters_solange

[Alessio Cortellini @ACortelliniMD]

It took us a while, but eventually this project on the #FamilyHistory in patients with NSCLC is now up and running at full speed! 📝🚀 https://t.co/1NpPOaSApH
Thanks to @fabricitarella @MassimoDiMaio75 @RobertoFerrara_ @PCascetta @KazukiTK1077 and co-authors!

[Priscilla Cascetta @PCascetta]

Thank you so much to @myESMO for this opportunity !
A brilliant preceptorship on #lungcancer 🫁 with outbreaking speakers and chairs at @TheChristieNHS and a good occasion to catch up with colleagues !

[ESMO - Eur. Oncology @myESMO]

Great to see you all at the 'ESMO - @TheChristieNHS Preceptorship on #LungCancer 2023' in Manchester exploring multidisciplinary managemt, SoC & future perspectives. There are many #ESMOPreceptorship courses in 2023 covering a wide range of topics 👉 https://t.co/H2dVY5eY9s
#lcsm

[Priscilla Cascetta @PCascetta]

Thanks to @myESMO for giving me the opportunity to meet again some special collegues and friends at the « ESMO advanced course of biomarkers for precision medicine» helded in Zurich 🇨🇭 !!
& congrats to @valerioiebba for his excellent presentation

[Priscilla Cascetta @PCascetta]

Out now in @Cancers_MDPI our review on #KRAS in #NSCLC, summarizing recent available evidences and ongoing trials, including targeted drugs and mechanisms of resistance.
Full 📃👇
https://t.co/HEur1qSOSj
@AriMarinel @vanesa_gregorc @dplanchard @NicolaNormanno

[Marco Tagliamento @M_Tagliamento]

Acquired resistance to sotorasib by plasma biomarker analysis in CodeBreaK100 (lung and CRC). Elegant presentation at #ASCO22 #ctDNA session.
The occurrence of multiple mutations characterises fast progressors among #NSCLC patients.
@OncoAlert #LCSM @ASCO

[Inserm @Inserm]

Des médecins chercheurs ont développé un #algorithme prédictif de fatigue sévère chez les patientes atteintes de #cancerdusein.

Cet outil de prévention personnalisée vise à orienter précocement vers des stratégies de prise en charge ciblées.

👉https://t.co/vFzbbda3sd